PFIZER INC Oppenheimer & Close LLC holding in Form 13-F
Oppenheimer & Close LLC reported holding of PFE
This chart displays the historical ownership data of PFE by Oppenheimer & Close LLC. At the end of Q3 2013 the holding was valued at $3,667,000. This decreased to $2,522,724 at the end of Q1 2025.
| Date | Holding Value |
|---|---|
| 3667000 | |
| 3807000 | |
| 3882000 | |
| 3575000 | |
| 3533000 | |
| 3717000 | |
| 4151000 | |
| 7904000 | |
| 3751000 | |
| 0 | |
| 6192000 | |
| 6499000 | |
| 8724000 | |
| 7766000 | |
| 7475000 | |
| 6311000 | |
| 7306363 | |
| 5788337 | |
| 5010671 | |
| 4613118 | |
| 4156124 | |
| 4019865 | |
| 3846131 | |
| 3250975 | |
| 2793874 | |
| 2522724 |
About PFIZER INC COM USD0 05
Pfizer is a global biopharmaceutical company that primarily provides medicines and vaccines addressing a range of diseases. Its main product categories include internal medicine, vaccines, inflammation and immunology, rare diseases, and oncology. Pfizer operates through three segments: Biopharma, which is the main segment, PC1 for contract development and manufacturing, and Pfizer Ignite, which offers R&D services to biotech firms.
Pfizer generates revenue through the sale of its biopharmaceutical products, with significant contributions from international markets such as China and Japan. The company's primary customers include wholesalers, hospitals, and government agencies, with vaccines often sold directly to the U.S. federal government and other international institutions. Pfizer's revenue is impacted by competition from generic and biosimilar manufacturers, pricing pressures from managed care organizations, and patent expirations.
Pfizer's operational structure includes divisions for oncology, U.S. commercial operations, and international commercial operations. Key factors impacting its business performance include competition, patent expirations, pricing and reimbursement challenges, and regulatory compliance. The company actively manages its R&D pipeline, focusing on enhancing existing products and discovering new indications through both internal efforts and external collaborations.
Disclaimer
FilingExplorer.com is not affiliated with, endorsed by, or in any way officially connected with any of the securities, funds, or companies mentioned on this site. The information provided is sourced from publicly available datasets and is presented for informational purposes only. While we strive for accuracy, we do not guarantee the completeness, timeliness, or accuracy of any information on this site. Users should not rely solely on this information for making investment decisions and should always conduct their own research or consult with a qualified financial advisor. Security and company summaries are based on public data available in recent SEC filings, and may not be entirely accurate. The mention of any security does not constitute a recommendation to buy, sell, or hold that or any other security. FilingExplorer.com is not responsible for any investment decisions made based on the information provided on this site.
See our Terms of Service
Oppenheimer & Close LLC reported holdings of PFE from Q3 2013 to Q1 2025
| Reporting period | Holding Type | Market Value | % of portfolio | Shares | Change in shares | % Change in shares |
|---|---|---|---|---|---|---|
| Q3 2013 | Stock | $3,667,000 | 2.61% | 127,651 | 0 | 0 |
| Q4 2013 | Stock | $3,807,000 | 3.29% | 124,285 | -3,366 | -2.64% |
| Q1 2014 | Stock | $3,882,000 | 3.24% | 120,851 | -6,800 | -5.33% |
| Q2 2014 | Stock | $3,575,000 | 2.88% | 120,464 | -387 | -0.32% |
| Q3 2014 | Stock | $3,533,000 | 2.9% | 119,464 | -1,000 | -0.83% |
| Q4 2014 | Stock | $3,717,000 | 3.12% | 119,314 | -150 | -0.13% |
| Q1 2015 | Stock | $4,151,000 | 3.5% | 119,314 | 0 | 0 |
| Q2 2015 | Stock | $7,904,000 | 3.29% | 235,728 | 116,414 | 97.57% |
| Q3 2015 | Stock | $3,751,000 | 3.19% | 119,415 | -116,313 | -49.34% |
| Q4 2015 | Stock | $0 | 0 | 0 | -119,415 | -100.0% |
| Q2 2021 | Stock | $6,192,000 | 5.74% | 158,140 | 158,140 | 0 |
| Q3 2021 | Stock | $6,499,000 | 6.23% | 151,120 | -7,020 | -4.44% |
| Q4 2021 | Stock | $8,724,000 | 8.21% | 147,756 | -3,364 | -2.23% |
| Q1 2022 | Stock | $7,766,000 | 6.7% | 150,026 | 2,270 | 1.54% |
| Q2 2022 | Stock | $7,475,000 | 8.53% | 142,581 | -7,445 | -4.96% |
| Q3 2022 | Stock | $6,311,000 | 6.83% | 144,226 | 1,645 | 1.15% |
| Q4 2022 | Stock | $7,306,363 | 7.18% | 142,591 | -1,635 | -1.13% |
| Q1 2023 | Stock | $5,788,337 | 5.73% | 141,871 | -720 | -0.5% |
| Q2 2023 | Stock | $5,010,671 | 5.2% | 136,605 | -5,266 | -3.71% |
| Q3 2023 | Stock | $4,613,118 | 4.6% | 139,075 | 2,470 | 1.81% |
| Q4 2023 | Stock | $4,156,124 | 3.79% | 144,360 | 5,285 | 3.8% |
| Q1 2024 | Stock | $4,019,865 | 3.49% | 144,860 | 500 | 0.35% |
| Q2 2024 | Stock | $3,846,131 | 3.38% | 137,460 | -7,400 | -5.11% |
| Q3 2024 | Stock | $3,250,975 | 2.61% | 112,335 | -25,125 | -18.28% |
| Q4 2024 | Stock | $2,793,874 | 2.3% | 105,310 | -7,025 | -6.25% |
| Q1 2025 | Stock | $2,522,724 | 2.08% | 99,555 | -5,755 | -5.46% |